PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients.

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication

MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter

Tyrosine kinase inhibition: the new front in HIV cure efforts

Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

Ethanolic extract of Artemisia campestris subsp. glutinosa (Besser) Batt. inhibits HIV-1 replication in vitro through the activity of terpenes and flavonoids on viral entry and NF-κB pathway.

International network for comparison of HIV neutralization assays: the NeutNet report II

Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression